ESBL-producing Escherichia coli bacteraemic urinary tract infections: Clinical and economic burden and antimicrobial stewardship opportunities in a retrospective cohort study

Read full text
Authors: Sílvia Gómez-Zorrilla, Grethel Rodríguez-Cabalé, Inmaculada López Montesinos, Soukaina Sara Alanti, Alejandra Franquet, Mariano Pascual-Aranda, Jesús Alonso-Carrillo, Alicia Rodríguez-Alarcón, Elena Sendra, Ana Siverio, Sandra Esteban-Cucó, Rosa Ana Sabaté
+4 more Xavier Duran-Jordà, Santiago Grau, Jesús Rodríguez-Baño, Juan Pablo Horcajada
Cited by: 3
References: 28

Abstract

BACKGROUND: The study aimed to assess the clinical and economic impact of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli bacteraemic UTIs (Ec-BUTI) and to evaluate the possibility of developing antimicrobial stewardship interventions. METHODS: Retrospective single-centre cohort study included all consecutive episodes of Ec-BUTI requiring hospitalisation from September 2020 to February 2023. PRIMARY OUTCOME: clinical failure. SECONDARY OUTCOME: hospital resource consumption, length of stay, 30-d recurrence and mortality and 90-d readmissions. Antimicrobial stewardship interventions were evaluated. A propensity score matching analysis was performed. RESULTS: Three hundred ten E. coli-BUTI episodes were included; 86 caused by ESBL-producing strains. The ESBL group had greater comorbidity burden than the non-ESBL group (median Charlson index 4 [IQR 2-6] vs. 2 [IQR 1-4]; P < 0.001) and more frequent inappropriate empirical therapy (40.7% vs. 3.6%; P < 0.001). Overall, an intravenous-to-oral switch was made within the first week in 172 (55.5%) episodes. In the ESBL group, an oral switch was made in 17 patients (19.7%), while no oral option was available in 48 (55.8%) based on susceptibility results. After adjustment, ESBL was not significantly associated with clinical failure (aOR 1.85, 95% CI 0.33-10.48), recurrence (aOR 1.98, 95% CI 0.70-5.62) or mortality (aHR 2.12, 95% CI 0.43-10.38). However, ESBL-producing Ec-BUTI was associated with longer stays (P = 0.014), higher pharmacy costs (P < 0.001) and independently increased overall hospitalisation costs by a median of €1493 (P = 0.022). CONCLUSIONS: ESBL-producing Ec-BUTI was associated with greater healthcare resource consumption and costs, though not with worse clinical outcomes. These findings highlight the economic impact of antimicrobial resistance and support antimicrobial stewardship.

Fields of Study & Subjects

Urinary Tract Infections Management Escherichia coli research studies Pediatric Urology and Nephrology Studies

Publication details

Journal / source
International Journal of Antimicrobial Agents
Publisher
Elsevier BV
Volume
67
Issue
6
Pages
107787–107787
Publication date
20 March 2026
Language
EN